Skip to main content
Midas Edge

Neuphoria Therapeutics Inc.

For the period ended Sep 30, 2025. Filed Nov 14, 2025.

View on SEC.gov

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Sep 30, 2025 · Filed Nov 14, 2025

NEUP$2.78+0.4%Stored close · as of Nov 6, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits
Contents

Condensed Consolidated Statement of Changes in Shareholders' Equity

Condensed Consolidated State ment of Changes in Shareholders' Equity (Unaudited)

Stock · Additional · AccumulatedOther · Total
Common Shares · Subscription · Paid-In · Comprehensive · Accumulated · Shareholders'
Shares · Amount · Receivable · Capital · Loss · Deficit · Equity
Balance at June 30, 20251,978,460$19$(94,685)$200,289,009$(2,845,066)$(178,346,703)$19,002,574
Issuance of common stock in connection with our ATM facility, net of offering costs of $0.1 million379,1534-3,158,930--3,158,934
Collection of subscription receivable--94,685---94,685
Share-based compensation---111,277--111,277
Other comprehensive income----49,221-49,221
Net loss-----(9,906,504)(9,906,504)
Balance at September 30, 20252,357,613$23$-$203,559,216$(2,795,845)$(188,253,207)$12,510,187
Balance at June 30, 20241,103,954$11$-$198,481,027$(3,013,595)$(177,977,071)$17,490,372
Exercise of pre-funded ADS warrants339,4083-406--409
Share issue costs---(227,747)--(227,747)
Share-based compensation---26,736--26,736
Other comprehensive income----585,381-585,381
Net loss-----(804,787)(804,787)
Balance at September 30, 20241,443,362$14$-$198,280,422$(2,428,214)$(178,781,858)$17,070,364
ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.